Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Oroco drills 26.48 m at 1.18% CuEq in Santo Tomas South Zone, Mexico

Oroco drills 26.48 m at 1.18% CuEq in Santo Tomas South Zone, Mexico

ReutersReuters2026/08/06 11:54
  • Oroco reported Phase 2 drill assays from the South Zone at its Santo Tomás copper project in Sinaloa, Mexico.
  • Hole S033 intersected 26.48 m grading 0.90% copper, 1.18% CuEq from 48 m depth.
  • Step-out holes S031 and S034 hit mineralization beyond the current inferred block model on the zone’s western side.
  • Southern drilling (S027, S030, S032) logged mixed oxide-sulphide copper, helping define the South Zone’s southern limit.
  • Work remains aimed at upgrading inferred resources to indicated for a pre-feasibility study targeted for Q2/Q3 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oroco Resource Corp. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage